Analyst Rating: Will Aurora Cannabis Inc (ACB) Stock Outperform the Market?

Wednesday, April 8, 2020 9:56 AM | InvestorsObserver Analysts

Wall Street is neutral on Aurora Cannabis Inc (ACB). On average, analysts give ACB a Sell rating. The average price target is $1.71, which means analysts expect the stock to increase by 111.11% over the next twelve months.

That average ranking earns ACB an Analyst Rating of 6, which is better than 6% of stocks based on data compiled by InvestorsObserver.

Overall Score - 2.9
Wall Street analysts are rating ACB a Sell today. Find out what this means to you and get the rest of the rankings on ACB!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.

Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Aurora Cannabis Inc Stock Today?

Aurora Cannabis Inc (ACB) stock is trading at $0.81 as of 9:48 AM on Wednesday, Apr 8, a rise of $0.01, or 1.11% from the previous closing price of $0.80. The stock has traded between $0.80 and $0.82 so far today. Volume today is less active than usual. So far 961,505 shares have traded compared to average volume of 34,309,840 shares.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Is Global Cord Blood Corp (CO) Stock a Great Value?

Denali Therapeutics Inc (DNLI) Stock Climbs 10.58% This Week; Should You Buy?

Should Replimune Group Inc (REPL) Stock be in Your Portfolio?

Should You Buy AcelRx Pharmaceuticals Inc (ACRX) Stock?

Sector Update: Health Care Stocks Slipping in Late Trade

Related Companies